



November 24, 2022

BSE Limited

Department of Corporate Services,
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,

MUMBAI - 400 001

National Stock Exchange of India Ltd.,

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),

MUMBAI - 400 051

Dear Sir/Madam,

**Re: Disclosure pursuant to Regulation 30 of the SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015**

Subject: U.S. FDA Inspection of the Company's Mandideep Unit-1 facility

We would like to inform you that the U.S. FDA inspected Lupin's Mandideep Unit-1 facility from November 14, 2022 to November 23, 2022. The inspection of the facility closed with issuance of a Form-483 with eight observations each for the Drug Product facility and API facility at the site.

We are committed to addressing the observations and will work with the U.S. FDA to resolve these issues at the earliest. We uphold quality and compliance issues with utmost importance and remain committed to be compliant with cGMP quality standards across all our facilities.

This may kindly be considered as a disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

For **LUPIN LIMITED**

R. V. SATAM
COMPANY SECRETARY
(ACS -1 1973)